Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.

Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2020 Feb 01;26(3):758 Authors: Passaro C, Alayo Q, DeLaura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H PMID: 32014888 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32014888?dopt=Abstract

Source: Clinical Cancer Research - January 31, 2020 Category: Cancer & Oncology Authors: Passaro C, Alayo Q, DeLaura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H Tags: Clin Cancer Res Source Type: research

More News: Cancer | Cancer & Oncology | Cold Sores | Herpes | Legislation